NASDAQ · TTRX
Turn Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TTRX: Nov 12, 2026
Turn Therapeutics Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.07.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · MarketBeat · BNK Invest- Fintel · Oct 23, 8:48 AM EDTWBB Securities Upgrades Turn Therapeutics to Hold from SellFintel reports that on October 23, 2026, WBB Securities upgraded their outlook for Turn Therapeutics (NASDAQGM:TTRX) from Sell to Hold. This rating action follows a prior action by the same firm on September 14, 2026, when WBB Securities downgraded the company from Hold to Sell.P
- Fintel · Oct 3, 4:46 AM EDTTurn Therapeutics Consensus Price Target Increased by 24.42% to $20.40The average one-year price target for Turn Therapeutics (NASDAQGM:TTRX) has been revised to $20.40 / share. This is an increase of 24.42% from the prior estimate of $16.40 dated September 11, 2026. These figures represent aggregate analyst targets and do not constitute a recomme
- RTTNews · Sep 9, 11:40 AM EDTTurn Therapeutics Names Former CDC Director Redfield As Chief Scientific Officer; Stock Up(RTTNews) – Turn Therapeutics Inc. (TTRX), a clinical-stage biotechnology company, on Wednesday announced the appointment of Robert R. Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention (CDC), as Chief Scientific Officer (CSO).
- RTTNews · Jul 20, 11:01 PM EDTTop Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch(RTTNews) – Today's top biotech gainers include Zhengye Biotechnology, a veterinary vaccine manufacturer, which surged, easing Nasdaq delisting concerns; Advanced Biomed, which gained after withdrawing its planned U.S. securities offering and reducing potential dilution concerns;
- MarketBeat · Jul 11, 1:02 PM EDTTurn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 ReadoutTurn Therapeutics (NASDAQ:TTRX) outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised approach was informed by an interim analysis of the first 50 completers in the ongoi
- RTTNews · Jun 2, 5:54 AM EDTTurn Therapeutics Reports Interim Phase 2 GX-03 Data In Atopic Dermatitis; Stock Up(RTTNews) – Turn Therapeutics Inc. (TTRX) announced interim findings from its ongoing Phase 2 GX-03 trial in adults with moderate-to-severe atopic dermatitis.
- RTTNews · Jun 1, 11:07 PM EDTTop Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch(RTTNews) – Monday's top gainers include Turn Therapeutics following its interim analysis findings from an atopic dermatitis study; Conexeu Science on progress in its B.R.E.A.S.T. bioprinting program; LIXTE Biotechnology and its strategic transformation; and Quanterix amid inside
- BNK Invest · Oct 24, 4:00 PM EDTFriday 10/24 Insider Buying Report: SNV, TTRXBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- NASDAQ.com · Oct 9, 8:29 AM EDTPre-Market Most Active for Oct 9, 2025 : TSLL, IONZ, NVDA, TSLQ, BITF, TTRX, ANVS, BMY, RKT, LAC, PATH, BHPThe NASDAQ 100 Pre-Market Indicator is up 6.94 to 25,143.56. The total Pre-Market volume is currently 308,890,181 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is -0.54 at $19.77, with 13,160,671 shar
- RTTNews · Oct 9, 12:03 AM EDTAfter-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally(RTTNews) – The after-hours session saw a flurry of bullish activity across U.S.-listed biotech and healthcare stocks, with Turn Therapeutics Inc. (TTRX) leading the charge. Shares of Turn Therapeutics surged 134.29% to $16.40, up $9.40 from its regular session close, following i
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Turn Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.